Advertisement
Advertisement
U.S. markets open in 8 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioAtla, Inc. (BCAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.08+0.38 (+4.94%)
At close: 04:00PM EDT
8.08 0.00 (0.00%)
After hours: 04:30PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Insider Monkey

    Australian Billionaire Kerr Neilson is Selling These 15 Stocks

    In this article, we discuss the 15 stocks Australian billionaire Kerr Neilson is selling. If you want to skip our analysis of Neilson’s history and investment philosophy, go directly to Australian Billionaire Kerr Neilson is Selling These 15 Stocks. Kerr Neilson is a billionaire investor who co-founded Platinum Asset Management with Andrew Clifford nearly 28 […]

  • TipRanks

    J.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider

    A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last three months, and at least one strategist believes that the market won’t go much lower from here. JPMorgan global market strategist Marko Kolanovic is taking a guardedly optimistic view of the coming year, noting: "We believe that any downside from here

  • PR Newswire

    Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

    Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced interim topline data update from the HTBA3011 in NSCLC and certain sarcomas.

Advertisement
Advertisement